CTOs on the Move

Rocket Pharmaceuticals

www.rocketpharma.com

 
Rocket Pharma (NASDAQ: RCKT) is a fully-integrated, clinical-stage company advancing numerous gene therapies that could cure rare childhood diseases. Rocket places enormous value on people and takes team member progress and well-being just as seriously as the progress and well-being of its pipeline. We are looking for hands-on team players that enjoy collaborating with colleagues who share a passion for seeking gene therapy cures for devastating diseases and making a difference for patients. Become an integral part of a small, highly productive team and help grow an entrepreneurial, scientifically driven organization that is increasingly recognized as a leading biotechnology innovator. ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Kinnari Patel
 President, Head of Research & Development and Chief Operating Officer Profile
Chris Stevens
 Chief Operating Officer Profile
Chantal Petit
 VP, Chief of Staff supporting the President/Head R&D/COO at Rocket Pharmaceuticals Profile
Mayo Pujols
 Executive Vice President and Chief Technical Officer Profile

Similar Companies

Sonitus Medical Inc.

Sonitus Medical Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Redwood Toxicology Laboratory

Redwood Toxicology Laboratory is a Santa Rosa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Diana Plants Sciences (Diana Group)

Diana Plants Sciences (Diana Group) is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nano Cures

The greatest health threats require more than an all-or-nothing approach. Nano represents a multi-layered set of solutions to usher in a new era in proactive, persistent health protection.

Lyell

We are entering a new era of medicine, where cancer is treated with cellular therapies: living, smart, targeted drugs. While enormous strides have been made, especially in hematologic cancers, the full promise of these therapies still lies ahead. Cell-based immunotherapies have yet to show substantial benefit in solid tumors, which represent the vast majority of cancers. Our goal is nothing less than to develop curative cell-based therapies for solid tumor cancers.